Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Last trade$15.36
Day change-$0.12 (-0.78%)
Day range$15.20 – $15.81
Volume402,841
Market cap$2.07B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.07B
Price / earnings
6.6×
Price / book
3.15×
Price / sales
6.45×
EV / sales
6.48×
EV / EBITDA
12.93×
Profitability
Earnings per share
$2.35
Return on assets
38.06%
Return on equity
47.8%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.08×
Current ratio
6.12×
Quick ratio
5.67×
Cash ratio
0.48×
Cash flow
Price / cash flow
11.71×
Price / free cash flow
11.72×
Free cash flow
$177.03M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AUPH, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$83.7M
$83.22M
$77.71M
$77.11M
$73.47M
$70.01M
$62.47M
$59.87M
Cost of revenue
$8.31M
$6.56M
$6.51M
$8.8M
$8.18M
$7.12M
$8.57M
$5.55M
Gross profit
$75.39M
$76.67M
$71.2M
$68.32M
$65.29M
$62.89M
$53.89M
$54.32M
Selling, general and administrative
$24.68M
$23.51M
$22.03M
$29.26M
$26.18M
$26.02M
$20.34M
$37.03M
Research and development
$16.61M
$13.05M
$7.47M
$10.9M
$8.44M
$7.43M
$5.74M
$8.11M
Total operating expenses
$40.03M
$30.32M
$29.78M
$49.68M
$35.55M
$42.81M
$32.04M
$56.14M
Operating income
$35.36M
$46.34M
$41.42M
$18.64M
$29.75M
$20.08M
$21.85M
-$1.83M
Interest expense
-$867K
-$948K
-$1.01M
-$1.05M
-$1.1M
-$1.12M
-$1.07M
-$1.15M
Income before taxes
$38.72M
$48.79M
$43.93M
$35.69M
$31.96M
$22.16M
$24.35M
$1.17M
Income taxes
$7.01M
$11.37M
$9.57M
-$175.1M
$411K
$643K
$1.01M
-$256K
Net income
$31.7M
$37.41M
$34.36M
$210.79M
$31.55M
$21.51M
$23.34M
$1.43M
Net income attributable to common shareholders
$31.7M
$37.41M
$34.36M
$210.79M
$31.55M
$21.51M
$23.34M
$1.43M
EBITDA
$40.2M
$51.18M
$46.24M
$23.5M
$34.61M
$25.06M
$28.24M
$18.39M
Basic earnings per share
$0.24
$0.29
$0.26
$1.60
$0.24
$0.16
$0.17
$0.01
Diluted earnings per share
$0.23
$0.28
$0.25
$1.53
$0.23
$0.16
$0.16
$0.01
Recent news
Company coverage with links to the original publishers.
Ionis Pharmaceuticals is expected to report Q3 2026 earnings with a year-over-year EPS decline of 63.9% to a loss of $1.00 per share, though revenues are projected to rise 14% to $178.93 million. With a negative Earnings ESP of -26.63% and Zacks Rank #3, the stock is not considered a compelling earnings-beat candidate. The company has a strong history of beating estimates in the last four quarters.
Aurinia Pharmaceuticals is expected to report Q3 2026 earnings of $0.20 per share, representing a 13% year-over-year decline, though revenues are projected to grow 18.7% to $87.2 million. With an Earnings ESP of 0% and Zacks Rank #3, the stock is not considered a compelling earnings-beat candidate. However, the company has a strong history of beating estimates, having beaten consensus EPS four times in the last four quarters.
Aurinia Pharmaceuticals (AUPH) is highlighted as a momentum stock worth watching, with a #3 Hold rating and B VGM Score. The biopharmaceutical company, focused on autoimmune kidney and rare diseases, has shown strong momentum with a Grade A Momentum Style Score and 4.4% gains over four weeks. One analyst raised fiscal 2026 earnings estimates to $0.91 per share, and the stock has demonstrated a +38.5% average earnings surprise.
The lupus nephritis market is projected to grow at a 7% CAGR through 2036, driven by increasing disease awareness, improved diagnosis, and expanding adoption of targeted therapies. The market was valued at USD 2.1 billion in 2025 across seven major markets. Three therapies have received FDA approval (belimumab, voclosporin, and obinutuzumab), while a robust pipeline of innovative treatments including CAR-T therapies, complement inhibitors, and monoclonal antibodies is expected to transform disease management.
The SLE and LN market is projected to grow from $2.4 billion in 2024 to $5.9 billion by 2034 (9.6% CAGR), driven by 10 late-stage pipeline drugs offering improved safety and efficacy over current generic treatments. However, growth faces headwinds from biosimilar competition and high treatment costs limiting adoption rates.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.